Familial_JJ risks_NNS of_IN breast_NN cancer_NN Abstract_NP |_SYM A_DT recent_JJ analysis_NN by_IN the_DT Collaborative_NP Group_NP on_IN Hormonal_NP Factors_NP in_IN Breast_NP Cancer_NP has_VBZ provided_VBN the_DT most_RBS precise_JJ quantification_NN to_TO date_VB of_IN the_DT familial_JJ risks_NNS of_IN breast_NN cancer_NN ._SENT The_DT familial_JJ relative_JJ risks_NNS are_VBP shown_VBN to_TO decrease_VB from_IN more_JJR than_IN fivefold_RB in_IN women_NNS younger_JJR than_IN age_NN 40_CD years_NNS with_IN a_DT first-degree_NN relative_NN aged_VBN younger_JJR than_IN 40_CD years_NNS at_IN diagnosis_NN ,_, to_TO 1.4-fold_NN in_IN women_NNS older_JJR than_IN 60_CD years_NNS with_IN a_DT relative_NN diagnosed_VBN over_IN age_NN 60_CD years_NNS ._SENT These_DT risks_NNS increase_VBP progressively_RB with_IN the_DT number_NN of_IN affected_JJ relatives_NNS ._SENT The_DT risks_NNS associated_VBN with_IN an_DT affected_JJ mother_NN and_CC an_DT affected_JJ sister_NN are_VBP similar_JJ ,_, and_CC the_DT relative_JJ (_( but_CC not_RB absolute_JJ )_) risks_NNS are_VBP similar_JJ in_IN subgroups_NNS defined_VBN by_IN other_JJ established_JJ breast_NN cancer_NN risk_NN factors_NNS ._SENT These_DT results_NNS provide_VBP a_DT useful_JJ basis_NN for_IN counselling_VBG of_IN women_NNS with_IN a_DT family_NN history_NN of_IN breast_NN cancer_NN ,_, and_CC they_PP have_VBP implications_NNS for_IN the_DT genetic_JJ basis_NN of_IN the_DT disease_NN ._SENT BRCA1_NP ,_, BRCA2_NP ,_, familial_JJ breast_NN cancer_NN ,_, reproductive_JJ factors_NNS ,_, The_DT increased_VBN risk_NN of_IN breast_NN cancer_NN among_IN women_NNS with_IN a_DT family_NN history_NN of_IN the_DT disease_NN is_VBZ one_CD of_IN the_DT oldest_JJS established_JJ facts_NNS about_IN the_DT disease_NN ._SENT This_DT familial_JJ aggregation_NN has_VBZ been_VBN the_DT inspiration_NN for_IN studies_NNS to_TO identify_VB breast_NN cancer_NN susceptibility_NN genes_NNS that_WDT have_VBP borne_VBN fruit_NN over_IN the_DT past_JJ decade_NN ,_, and_CC has_VBZ been_VBN the_DT basis_NN for_IN defining_VBG high-risk_JJ groups_NNS for_IN intervention_NN studies_NNS (_( e.g._FW with_IN tamoxifen_NN )_) ._SENT Yet_RB despite_IN the_DT fact_NN that_IN questions_NNS about_IN family_NN history_NN are_VBP asked_VBN in_IN almost_RB every_DT epidemiological_JJ study_NN of_IN breast_NN cancer_NN ,_, some_DT important_JJ questions_NNS about_IN the_DT quantitative_JJ relationship_NN between_IN family_NN history_NN relationship_NN have_VBP not_RB been_VBN answered_VBN with_IN precision_NN ._SENT Among_IN these_DT questions_NNS are_VBP the_DT magnitude_NN of_IN the_DT risk_NN according_VBG to_TO the_DT age_NN of_IN the_DT women_NNS and_CC the_DT age_NN of_IN their_PP$ affected_JJ relative(s)_NN ,_, the_DT precise_JJ effect_NN of_IN numbers_NNS and_CC types_NNS of_IN affected_JJ relatives_NNS ,_, and_CC the_DT joint_JJ effects_NNS of_IN family_NN history_NN and_CC other_JJ known_JJ risk_NN factors_NNS ._SENT Since_IN only_JJ ~10_NN --_: 15_CD %_NN of_IN women_NNS with_IN breast_NN cancer_NN typically_RB report_VB a_DT family_NN history_NN of_IN breast_NN cancer_NN ,_, individual_JJ epidemiological_JJ studies_NNS have_VBP not_RB had_VBN the_DT power_NN to_TO answer_VB these_DT questions_NNS precisely_RB ._SENT The_DT recent_JJ analysis_NN by_IN the_DT Collaborative_NP Group_NP on_IN Hormonal_NP Factors_NP in_IN Breast_NP Cancer_NP goes_VBZ a_DT long_JJ way_NN toward_IN resolving_VBG some_DT of_IN these_DT uncertainties_NNS ._SENT This_DT group_NN has_VBZ brought_VBN together_RB data_NNS from_IN 52_CD studies_NNS ,_, originally_RB to_TO evaluate_VB the_DT effects_NNS of_IN oral_JJ contraceptives_NNS and_CC hormone_NN replacement_NN therapy_NN ._SENT In_IN the_DT current_JJ overview_NN ,_, the_DT group_NN examine_VB risks_NNS according_VBG to_TO family_NN history_NN of_IN breast_NN cancer_NN in_IN a_DT first-degree_NN relative_JJ in_IN over_IN 58,000_CD cases_NNS and_CC in_IN nearly_RB 102,000_CD controls_NNS ._SENT The_DT main_JJ results_NNS from_IN the_DT overview_NN are_VBP straightforward_JJ to_TO summarise_VB ._SENT The_DT results_NNS of_IN the_DT study_NN are_VBP mainly_RB expressed_VBN in_IN terms_NNS of_IN the_DT risk_NN ratio_NN (_( or_CC relative_JJ risk_NN )_) of_IN breast_NN cancer_NN associated_VBN with_IN a_DT family_NN history_NN ;_: that_WDT is_VBZ ,_, the_DT ratio_NN of_IN the_DT incidence_NN rate_NN of_IN breast_NN cancer_NN in_IN relatives_NNS of_IN breast_NN cancer_NN cases_NNS to_TO the_DT incidence_NN in_IN the_DT relatives_NNS of_IN controls_NNS ._SENT These_DT risk_NN ratios_NNS were_VBD estimated_VBN from_IN the_DT case-control_NN studies_NNS in_IN the_DT usual_JJ way_NN ,_, and_CC we_PP refer_VBP to_TO them_PP as_IN '_'' familial_JJ relative_JJ risks_NNS '_POS ._SENT As_IN anticipated_VBN ,_, the_DT familial_JJ relative_JJ risk_NN of_IN breast_NN cancer_NN declines_VBZ progressively_RB as_RB both_CC the_DT age_NN at_IN diagnosis_NN of_IN the_DT case_NN and_CC the_DT age_NN at_IN diagnosis_NN of_IN the_DT relative_JJ increases_NNS ._SENT The_DT estimated_JJ relative_JJ risk_NN is_VBZ thus_RB 5.7-fold_JJ when_WRB both_CC the_DT case_NN and_CC the_DT relative_JJ are_VBP younger_JJR than_IN age_NN 40_CD years_NNS ,_, but_CC is_VBZ only_RB 1.4-fold_JJ when_WRB both_DT are_VBP aged_VBN older_JJR than_IN 60_CD years_NNS ._SENT (_( An_DT anomalous_JJ observation_NN here_RB is_VBZ that_IN the_DT relative_JJ risks_NNS decline_VBP more_RBR clearly_RB with_IN age_NN of_IN the_DT case_NN than_IN with_IN age_NN of_IN the_DT relative_JJ ;_: for_IN cases_NNS older_JJR than_IN age_NN 60_CD years_NNS ,_, there_EX was_VBD no_DT apparent_JJ trend_NN in_IN risk_NN by_IN age_NN of_IN relative_JJ ._SENT This_DT anomaly_NN might_MD be_VB explicable_JJ by_IN inaccuracies_NNS in_IN the_DT reporting_NN of_IN a_DT relative_NN 's_POS age_NN at_IN diagnosis_NN ._SENT )_) This_DT pattern_NN of_IN risk_NN was_VBD essentially_RB the_DT same_JJ whether_IN the_DT affected_JJ relative_NN was_VBD a_DT mother_NN or_CC a_DT sister_NN ._SENT For_IN women_NNS aged_VBN younger_JJR than_IN 50_CD years_NNS ,_, the_DT risk_NN ratio_NN associated_VBN with_IN having_VBG a_DT relative_NN diagnosed_VBD younger_JJR than_IN age_NN 50_CD years_NNS was_VBD 2.41_CD (_( 95_CD %_NN confidence_NN interval_NN ,_, 1.86_CD --_: 3.12_CD )_) for_IN an_DT affected_JJ mother_NN and_CC was_VBD 3.18_CD (_( 95_CD %_NN confidence_NN interval_NN ,_, 2.15_CD --_: 4.72_CD )_) for_IN having_VBG an_DT affected_JJ sister_NN ._SENT For_IN women_NNS aged_VBN older_JJR than_IN 50_CD years_NNS ,_, the_DT risk_NN ratio_NN associated_VBN with_IN having_VBG a_DT relative_NN diagnosed_VBD older_JJR than_IN 50_CD years_NNS was_VBD 1.60_CD (_( 95_CD %_NN confidence_NN interval_NN ,_, 1.38_CD --_: 1.84_CD )_) for_IN an_DT affected_JJ mother_NN and_CC was_VBD 1.44_CD (_( 95_CD %_NN confidence_NN interval_NN ,_, 1.19_CD --_: 1.73_CD )_) for_IN an_DT affected_JJ sister_NN ._SENT The_DT second_JJ observation_NN was_VBD that_IN the_DT risk_NN increased_VBD progressively_RB with_IN numbers_NNS of_IN affected_JJ relatives_NNS ._SENT The_DT risk_NN ratios_NNS were_VBD 1.80_CD with_IN one_CD affected_JJ relative_NN ,_, 2.93_CD with_IN two_CD affected_JJ relatives_NNS and_CC 3.90_CD (_( albeit_IN with_IN wide_JJ confidence_NN limits_NNS )_) with_IN three_CD or_CC more_JJR affected_JJ relatives_NNS ._SENT Third_JJ ,_, the_DT investigators_NNS performed_VBD detailed_JJ analyses_NNS to_TO examine_VB the_DT effects_NNS of_IN other_JJ known_VBN breast_NN cancer_NN risk_NN factors_NNS in_IN women_NNS with_IN and_CC without_IN a_DT family_NN history_NN ,_, and_CC conversely_RB the_DT effect_NN of_IN family_NN history_NN in_IN women_NNS in_IN categories_NNS defined_VBN by_IN other_JJ risk_NN factors_NNS ._SENT They_PP found_VBD that_IN the_DT relative_JJ risks_NNS associated_VBN with_IN other_JJ risk_NN factors_NNS were_VBD essentially_RB identical_JJ in_IN women_NNS with_IN and_CC without_IN a_DT family_NN history_NN ._SENT In_IN women_NNS with_IN a_DT family_NN history_NN ,_, risk_NN thus_RB reduced_VBN with_IN increasing_VBG parity_NN ,_, with_IN earlier_JJR age_NN at_IN first_JJ child_NN ,_, and_CC with_IN earlier_JJR age_NN at_IN menopause_NN to_TO a_DT similar_JJ relative_JJ extent_NN (_( but_CC ,_, therefore_RB ,_, a_DT larger_JJR absolute_JJ extent_NN )_) as_IN in_IN women_NNS without_IN a_DT family_NN history_NN ._SENT There_EX was_VBD no_DT significant_JJ evidence_NN of_IN an_DT association_NN of_IN oral_JJ contraceptives_NNS or_CC hormone_NN replacement_NN therapy_NN in_IN women_NNS with_IN a_DT family_NN history_NN ,_, but_CC the_DT confidence_NN limits_VBZ for_IN these_DT comparisons_NNS were_VBD extremely_RB wide_JJ and_CC the_DT results_NNS were_VBD consistent_JJ with_IN effects_NNS similar_JJ to_TO the_DT small_JJ increased_VBN risks_NNS seen_VBN in_IN the_DT general_JJ population_NN ._SENT Finally_RB ,_, the_DT investigators_NNS examined_VBD the_DT effect_NN of_IN tumour_NN spread_NN on_IN familial_JJ risk_NN ,_, but_CC found_VBD that_IN the_DT familial_JJ risks_NNS were_VBD essentially_RB the_DT same_JJ whether_IN or_CC not_RB the_DT tumour_NN was_VBD localised_VBN to_TO the_DT breast_NN at_IN diagnosis_NN ._SENT An_DT obvious_JJ concern_NN in_IN any_DT studies_NNS of_IN familial_JJ risk_NN is_VBZ the_DT accuracy_NN of_IN reporting_VBG of_IN cancer_NN diagnoses_NNS in_IN relatives_NNS ._SENT Other_JJ studies_NNS have_VBP indicated_VBN that_IN breast_NN cancer_NN is_VBZ fairly_RB accurately_RB reported_VBN ,_, certainly_RB in_IN comparison_NN with_IN other_JJ cancer_NN types_NNS (_( for_IN example_NN ,_, )_) ,_, but_CC there_EX is_VBZ some_DT inaccuracy_NN ,_, and_CC hence_RB potentially_RB some_DT bias_NN in_IN favour_NN of_IN reporting_VBG of_IN cancers_NNS by_IN cases_NNS ._SENT However_RB ,_, the_DT investigators_NNS found_VBD the_DT familial_JJ risks_NNS from_IN the_DT cohort_NN studies_NNS alone_RB (_( which_WDT are_VBP not_RB susceptible_JJ to_TO this_DT bias_NN )_) to_TO be_VB very_RB similar_JJ ._SENT The_DT main_JJ application_NN of_IN these_DT results_NNS will_MD be_VB to_TO genetic_JJ counselling_VBG and_CC identification_NN of_IN high-risk_JJ women_NNS for_IN screening_NN and_CC intervention_NN studies_NNS ._SENT There_EX are_VBP clearly_RB some_DT important_JJ limitations_NNS in_IN this_DT respect_NN ._SENT Most_RBS obviously_RB ,_, the_DT overview_NN did_VBD not_RB include_VB data_NNS on_IN genotypes_NNS at_IN known_VBN susceptibility_NN genes_NNS (_( data_NNS that_WDT would_MD rarely_RB be_VB available_JJ in_IN such_JJ studies_NNS )_) ,_, so_RB these_DT risk_NN estimates_NNS would_MD not_RB apply_VB in_IN families_NNS where_WRB ,_, for_IN example_NN ,_, BRCA1_NP or_CC BRCA2_NP mutation_NN testing_NN had_VBD taken_VBN place_NN ._SENT At_IN least_JJS for_IN the_DT present_JJ ,_, however_RB ,_, genetic_JJ testing_NN is_VBZ mostly_RB restricted_VBN to_TO women_NNS with_IN a_DT strong_JJ family_NN history_NN (_( e.g._FW three_CD or_CC more_JJR affected_JJ relatives_NNS )_) so_IN these_DT empirical_JJ estimates_NNS will_MD still_RB be_VB of_IN value_NN to_TO the_DT large_JJ majority_NN of_IN women_NNS ._SENT A_DT more_RBR subtle_JJ problem_NN is_VBZ that_IN no_DT data_NNS on_IN ages_NNS of_IN unaffected_JJ female_JJ relatives_NNS were_VBD included_VBN ._SENT Clearly_RB ,_, in_IN practice_NN ,_, the_DT number_NN and_CC ages_NNS of_IN unaffected_JJ female_JJ relatives_NNS do_VBP affect_NN risk_NN (_( although_IN to_TO a_DT lesser_JJR extent_NN than_IN affected_JJ relatives_NNS do_VBP )_) ._SENT Also_RB ,_, the_DT overview_NN had_VBD insufficient_JJ data_NNS to_TO evaluate_VB risks_NNS according_VBG to_TO whether_IN a_DT daughter_NN was_VBD affected_VBN ,_, and_CC no_DT data_NNS at_IN all_DT on_IN second-degree_NN or_CC more_JJR distant_JJ relatives_NNS (_( generally_RB poorly_RB recorded_VBN in_IN case-control_NN studies_NNS )_) ._SENT The_DT latter_JJ two_CD issues_NNS might_MD be_VB answered_VBN more_RBR reliably_RB through_IN cohort_NN studies_NNS of_IN families_NNS ,_, such_JJ as_IN those_DT based_VBN on_IN the_DT Swedish_NP Population_NP Family_NP Register_NP ._SENT The_DT overview_NN did_VBD not_RB consider_VB risks_NNS according_VBG to_TO cancers_NNS other_JJ than_IN breast_NN cancer_NN in_IN relatives_NNS ._SENT Other_JJ studies_NNS ,_, however_RB ,_, have_VBP indicated_VBN that_IN ,_, with_IN exception_NN of_IN a_DT well_RB established_VBN but_CC modest_JJ risk_NN of_IN ovarian_JJ cancer_NN (_( probably_RB explicable_JJ in_IN terms_NNS of_IN the_DT association_NN of_IN both_DT cancers_NNS with_IN BRCA1/2_NP mutations_NNS )_) and_CC an_DT association_NN with_IN childhood_NN sarcoma_NN (_( perhaps_RB entirely_RB due_JJ to_TO TP53_NP mutations_NNS )_) ,_, there_EX is_VBZ little_JJ or_CC no_DT excess_JJ risk_NN of_IN breast_NN cancer_NN associated_VBN with_IN a_DT family_NN history_NN of_IN other_JJ cancers_NNS ._SENT Although_IN the_DT aim_NN of_IN the_DT overview_NN was_VBD to_TO present_VB empirical_JJ risk_NN estimates_NNS ,_, these_DT estimates_NNS do_VBP raise_VB some_DT interesting_JJ issues_NNS with_IN regard_NN to_TO the_DT genetics_NN of_IN breast_NN cancer_NN ._SENT Two_CD studies_NNS have_VBP estimated_VBN that_IN mutations_NNS in_IN the_DT BRCA1_NP and_CC BRCA2_NP genes_NNS only_RB account_VBP for_IN approximately_RB 15_CD %_NN of_IN the_DT excess_JJ familial_JJ risk_NN of_IN the_DT disease_NN ,_, while_IN the_DT contribution_NN of_IN the_DT other_JJ known_JJ breast_NN cancer_NN susceptibility_NN genes_NNS (_( TP53_NP ,_, PTEN_NP ,_, CHK2_NP and_CC ATM_NN )_) is_VBZ even_RB smaller_JJR ._SENT The_DT contribution_NN of_IN known_VBN genes_NNS is_VBZ higher_JJR than_IN this_DT in_IN certain_JJ populations_NNS where_WRB specific_JJ BRCA1_NP or_CC BRCA2_NP mutations_NNS have_VBP become_VBN common_JJ as_IN a_DT result_NN of_IN founder_NN effects_NNS ._SENT These_DT populations_NNS include_VBP Iceland_NP ,_, Ashkenazi_NP Jewish_JJ populations_NNS and_CC parts_NNS of_IN Poland_NP ._SENT In_IN most_JJS Western_JJ populations_NNS ,_, however_RB ,_, the_DT observed_JJ familial_JJ risks_NNS are_VBP largely_RB the_DT result_NN either_CC of_IN other_JJ genes_NNS or_CC of_IN nongenetic_JJ familial_JJ risk_NN factors_NNS ._SENT While_IN the_DT possibility_NN of_IN the_DT latter_NN cannot_MD be_VB definitively_RB ruled_VBN out_RP ,_, results_NNS from_IN twin_JJ studies_NNS suggest_VBP that_IN the_DT majority_NN of_IN the_DT familial_JJ risk_NN is_VBZ in_IN fact_NN genetic_JJ in_IN origin_NN ._SENT (_( Since_IN adjustment_NN for_IN known_VBN reproductive_JJ and_CC other_JJ breast_NN cancer_NN risk_NN factors_NNS had_VBD essentially_RB no_DT effect_NN on_IN the_DT familial_JJ risks_NNS ,_, nongenetic_JJ contributors_NNS to_TO the_DT familial_JJ risk_NN ,_, if_IN there_EX are_VBP any_DT ,_, must_MD presumably_RB be_VB unrelated_JJ to_TO the_DT known_VBN risk_NN factors_NNS ._SENT )_) The_DT absence_NN of_IN substantial_JJ difference_NN in_IN risk_NN by_IN type_NN of_IN affected_JJ relative_NN (_( i.e._FW affected_JJ mother_NN versus_CC affected_JJ sister_NN )_) suggests_VBZ that_IN the_DT important_JJ genes_NNS are_VBP likely_JJ to_TO act_VB dominantly_RB or_CC additively_RB on_IN risk_NN ,_, but_CC not_RB to_TO act_VB recessively_RB (_( recessive_JJ susceptibility_NN genes_NNS give_VBP rise_NN to_TO higher_JJR risks_NNS in_IN siblings_NNS than_IN in_IN parents_NNS or_CC offspring_NNS )_) ._SENT Some_DT studies_NNS using_VBG a_DT family-based_JJ cohort_NN approach_NN have_VBP found_VBN higher_JJR risks_NNS in_IN siblings_NNS ,_, and_CC these_DT notably_RB include_VBP studies_NNS of_IN cases_NNS diagnosed_VBN at_IN a_DT particularly_RB young_JJ age_NN ._SENT These_DT results_NNS do_VBP not_RB necessarily_RB conflict_NN with_IN the_DT overview_NN ,_, since_IN the_DT risk_NN estimates_VBZ from_IN the_DT overview_NN are_VBP imprecise_JJ at_IN young_JJ ages_NNS ._SENT Conversely_RB ,_, it_PP may_MD be_VB that_IN the_DT higher_JJR risk_NN to_TO siblings_NNS in_IN the_DT cohort_NN studies_NNS is_VBZ due_JJ at_IN least_JJS in_IN part_NN to_TO cohort_NN effects_NNS on_IN background_NN incidence_NN rates_NNS ,_, and_CC to_TO the_DT artefactually_RB low_JJ rate_NN of_IN breast_NN cancer_NN in_IN mothers_NNS who_WP are_VBP ,_, by_IN definition_NN ,_, parous_JJ ._SENT The_DT pattern_NN of_IN risk_NN by_IN the_DT number_NN of_IN affected_JJ relatives_NNS is_VBZ also_RB revealing_JJ ._SENT The_DT fact_NN that_IN the_DT risk_NN increases_VBZ progressively_RB with_IN the_DT number_NN of_IN affected_JJ relatives_NNS suggests_VBZ the_DT effect_NN of_IN a_DT fairly_RB large_JJ number_NN of_IN genetic_JJ risk_NN groups_NNS ,_, consistent_JJ with_IN ,_, for_IN example_NN ,_, a_DT polygenic_JJ model_NN as_IN proposed_VBN by_IN Antoniou_NP et_FW al._FW ._SENT The_DT trend_NN in_IN relative_JJ risk_NN with_IN age_NN suggests_VBZ that_IN (_( like_IN BRCA1_NP and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, BRCA2_NP )_) some_DT or_CC all_DT of_IN the_DT susceptibility_NN genes_NNS involved_VBN are_VBP likely_JJ to_TO confer_VB a_DT higher_JJR relative_JJ risk_NN at_IN young_JJ ages_NNS ._SENT Finally_RB ,_, the_DT similarity_NN of_IN the_DT risk_NN ratios_NNS for_IN other_JJ risk_NN factors_NNS in_IN women_NNS with_IN and_CC without_IN a_DT family_NN history_NN suggest_VBP that_IN these_DT risk_NN factors_NNS act_VBP to_TO a_DT similar_JJ extent_NN in_IN women_NNS at_IN any_DT level_NN of_IN genetic_JJ susceptibility_NN ._SENT Of_IN course_NN ,_, one_PP cannot_MD necessarily_RB assume_VB that_IN this_DT will_MD hold_VB for_IN carriers_NNS of_IN particular_JJ susceptibility_NN mutations_NNS ._SENT Studies_NNS of_IN BRCA1_NP and_CC BRCA2_NP mutation_NN carriers_NNS have_VBP shown_VBN that_IN early_JJ menopause_NN does_VBZ have_VB the_DT expected_VBN protective_JJ effect_NN in_IN these_DT groups_NNS ,_, but_CC the_DT effects_NNS of_IN other_JJ risk_NN factors_NNS such_JJ as_IN parity_NN have_VBP not_RB been_VBN definitively_RB established_VBN ._SENT What_WP are_VBP the_DT implications_NNS for_IN genetic_JJ counselling_VBG ?_SENT Perhaps_RB the_DT most_RBS important_JJ is_VBZ that_IN the_DT absolute_JJ risk_NN of_IN breast_NN cancer_NN in_IN women_NNS with_IN just_RB one_CD affected_JJ relative_NN is_VBZ relatively_RB modest_JJ ,_, even_RB when_WRB the_DT relative_NN is_VBZ diagnosed_VBN at_IN a_DT young_JJ age_NN (_( the_DT authors_NNS estimate_VBP a_DT cumulative_JJ risk_NN of_IN 16_CD %_NN by_IN age_NN 80_CD years_NNS for_IN women_NNS with_IN a_DT relative_NN diagnosed_VBD younger_JJR than_IN age_NN 40_CD years_NNS )_) ._SENT The_DT risks_NNS associated_VBN with_IN having_VBG larger_JJR numbers_NNS of_IN affected_JJ relatives_NNS are_VBP more_RBR substantial_JJ ,_, and_CC referral_NN to_TO cancer_NN genetics_NNS clinics_NNS should_MD reflect_VB this_DT ._SENT The_DT results_NNS of_IN the_DT present_JJ study_NN also_RB imply_VBP that_IN the_DT effects_NNS of_IN reproductive_JJ and_CC hormonal_JJ risk_NN factors_NNS could_MD be_VB usefully_RB incorporated_VBN into_IN genetic_JJ counselling_VBG ._SENT Since_IN the_DT effects_NNS of_IN family_NN history_NN and_CC these_DT other_JJ risk_NN factors_NNS on_IN breast_NN cancer_NN risks_NNS appear_VBP to_TO combine_VB in_IN roughly_RB multiplicative_JJ fashion_NN ,_, the_DT absolute_JJ effects_NNS of_IN risk_NN factors_NNS in_IN individuals_NNS with_IN a_DT strong_JJ family_NN history_NN can_MD be_VB substantial_JJ ._SENT 